RxDoctor Payments Data

Kylene Schroer, APRN

Psychiatric/Mental Health · Grand Island, NENPI 1033317722

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 193 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,897, more than ten times the $87 reported in 2021.

$3,134in general payments, 2019–2025

Across 193 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$713
  • Otsuka America Pharmaceutical, Inc.$459
  • E.r. Squibb & Sons, L.L.C.$292
  • Axsome Therapeutics, Inc.$271
  • Johnson & Johnson$190
  • Alkermes, Inc.$163
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,134100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,134 in reported general payments places this provider in the 75th percentile of 255 psychiatric/mental health providers in Nebraska.

See all psychiatric/mental health providers in Nebraska

Medicare billing

Part B allowed, 2024
$6,190
Medicare patients
15
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate11$38,886
VraylarCariprazine Hcl23$33,683
FetzimaLevomilnacipran Hcl15$7,288
Lurasidone Hcl24$5,187
Atomoxetine Hcl17$2,210
Bupropion XlBupropion Hcl71$826
Duloxetine Hcl28$650
Naltrexone Hcl13$648
Aripiprazole13$475
Hydroxyzine Hcl31$455
Buspirone Hcl29$439
Lamotrigine40$351
Methylphenidate ErMethylphenidate Hcl11$334
Clonazepam25$280
Amitriptyline Hcl22$257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Fetzima$713$40,97138 claims
Johnson & JohnsonInvega Sustenna$190$38,88611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 255 psychiatric/mental health providers in Nebraska.

Other psychiatric/mental health in Grand Island

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →